The radiation delivered in this method is in a moderate dose range (3–10 Gy/fx), which promotes MHC class I molecule expression on the tumor cells, facilitates the release of TAAs, and activates the CD8+ T cell anti‐tumoral response against the primary tumor or even metastases.13 Here, CD8A is linked to neoplasm.